Invesco
MAZE

Invesco’s Maze Therapeutics MAZE Stock Holding History

Invesco’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$847K Sell
28,372
-58,047
-67% -$1.52M ﹤0.01% 3006
2026
Q1 		$2.58M Sell
86,419
-47,614
-36% -$2.1M ﹤0.01% 2433
2025
Q4 		$5.55M Buy
134,033
+1,971
+1% +$67.7K ﹤0.01% 2200
2025
Q3 		$3.42M Buy
132,062
+113,632
+617% +$1.92M ﹤0.01% 2394
2025
Q2 		$226K Sell
18,430
-2,122
-10% -$22.1K ﹤0.01% 3478
2025
Q1 		$226K Buy
+20,552
New +$247K ﹤0.01% 3460

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Invesco's MAZE Position: Q2 2026 in Review

Invesco reduced its Maze Therapeutics (MAZE) stake by 67% in Q2 2026, selling an estimated $1.52M and leaving 28,372 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

Invesco first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.55M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Invesco held 28,372 shares of Maze Therapeutics worth $847K as of Q2 2026.
  • Invesco sold 58,047 Maze Therapeutics shares in Q2 2026, an estimated $1.52M.
  • Maze Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3006 holding.
  • Invesco first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Invesco's Maze Therapeutics position peaked at $5.55M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.